Adaptimmune's SPEAR T-cells targeting MAGE-A4 an Orphan Drug in U.S.

|About: Adaptimmune Therapeutics plc (ADAP)|By:, SA News Editor

The FDA has granted Orphan Drug Designation (ODD) to Adaptimmune Therapeutics' (NASDAQ:ADAP) SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.

Adaptimmune is currently investigating its ADP-A2M4 SPEAR T-cells in two types of sarcoma: synovial sarcoma and MRCLS.

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

Subscribe for full text news in your inbox